Thursday 16 October, 2025
Introduction: Despite proven clinical action of angiogenic inhibitors [1], recent experimental evidence also suggests differential effects of these drugs on…
Read moreAbstracts
External validation of a para-aminosalicylic acid population pharmacokinetics model using the ncappc R package
Thursday 16 October, 2025
Introduction: Para-aminosalicylic acid (PAS) is one of the essential add-on Group C medicines recommended by the World Health Organisation for the…
Read moreDose optimization based on control and system theory: Case of Meropenem
Thursday 16 October, 2025
Objectives: Thanks to mathematical modeling, clinical pharmacology is an interesting and promising field of application of control and system theory…
Read moreExposure–response modelling of aripiprazole and brexpiprazole in adults and adolescents with schizophrenia to support extrapolation of efficacy in adolescents
Thursday 16 October, 2025
Introduction: The FDA recently released a general advice letter to sponsors, permitting the effectiveness of second-generation antipsychotics for the treatment…
Read moreOptimization of dosing strategy for Colistin using population pharmacokinetic model based on the Bayesian inference
Thursday 16 October, 2025
Objectives : With increasing incidence of infections caused by multi drug resistance (MDR) Gram negative pathogen and paucity of new…
Read morePopulation Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis Patients
Thursday 16 October, 2025
Objectives: Isoniazid (INH) is a drug used in the first-line treatment of tuberculosis (TB). Interindividual variability (IIV) of INH pharmacokinetics…
Read moreModeling the relationship between plasma and intracellular pharmacokinetics of bedaquiline and its metabolite M2 in South African patients with rifampicin-resistant tuberculosis
Thursday 16 October, 2025
Objectives: Tuberculosis is one of the leading causes of mortality from a single pathogen worldwide [1]. Meanwhile, drug-resistant tuberculosis is…
Read morePopulation pharmacokinetic analysis of elafibranor and metabolite GFT1007 to support exposure-response characterization and dose selection in patients with primary biliary cholangitis
Thursday 16 October, 2025
Objectives: Elafibranor is a dual peroxisome proliferator-activated receptor α/δ agonist. It is an orally administered, liver-targeted drug candidate developed for…
Read morePopulation Pharmacokinetic-Pharmacodynamic Modeling of Escitalopram in Patients with Obsessive-Compulsive Disorder Using Yale-Brown Obsessive Compulsive Scale
Thursday 16 October, 2025
Objectives: The aim of this study was to develop pharmacokinetic-pharmacodynamic (PKPD) model of escitalopram concentration and its therapeutic effect on…
Read moreAccelerating robust virtual patient (VP) population generation by substituting ODE solving with simple parameter comparisons
Thursday 16 October, 2025
Introduction/Objectives: The generation of Virtual Patients (VPs) is a common task in Quantitative System Pharmacology (QSP). In the most classical…
Read more